35387-22-5

Usage

InChI:InChI=1/C12H10O2/c1-8-5-6-9-3-2-4-10(12(13)14)11(9)7-8/h2-7H,1H3,(H,13,14)

Upstream product

• 41774-41-8 acetyl-8 methyl-2 naphtalene 
• 124-38-9 carbon dioxide 
• 7511-27-5 1-bromo-7-methylnaphthalene 
• 63409-06-3 7-methyl-1-naphthalenecarboxaldehyde 
• 91-57-6 2-Methylnaphthalene 
• 91902-61-3 methyl 7-methyl-1-naphthalenecarboxylate 
• 127810-66-6 8-bromo-2-hydroxy-2-methyl-1,2,3,4-tetrahydronaphthalene 
• 117294-21-0 8-bromo-2-tetralone 
• 162150-56-3 3,4-dihydro-7-methylnaphthalene-1-carbonitrile 
• 38879-97-9 7-methylnaphthalene-1-carbonitrile 

Relevant academic research and scientific papers

11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.

Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases

Compounds of the general formula wherein R is selected from the group consisting essentially of hydrogen, methyl, ethyl, phenyl, a carboxyl, or naphthyl substituted or a carbonyl substituted, alkyl of from 3 to 20 carbon atoms, a mono, bi or tri cyclic aryl or substituted aryl for the inhibition of phosphatase enzymes, including metallophosphatases; and, novel methods for synthesizing such compounds. The methods of use include the administration of an effective amount of the compound to provide effective phosphatase inhibition and therapeutic use to treat or prevent certain diseases, which utilize specific phosphatase enzymes.

Synthesis of 8,8′-Disubstituted 1,1′-Binaphthyls Stable to Atropisomerization: 2,2′-Dimethyl-1,1′-binaphthalene-8,8′-diol and 2,2′-Dimethyl-8,8′-bis(4-tert-butyloxazolyl)-1,1′-binaphthyl

Axially chiral binaphthyls 3a and 3b were synthesized taking, advantage of Ullman coupling of 4a and 4b, respectively. The binaphthyls were shown to be stable to atropisomerization. Binaphthol 3b was resolved with (-)-(1S)-menthyl chloroformate (11). R-axis diastereomer of bisoxazoline 3b was used for enantioselective cyclopropanation of styrene with ethyl diazoacetate.

cis-BIS(7-METHYLNAPHTH-1-YL)BIS(TRIPHENYLPHOSPHAN)PLATIN(II)

From the reaction of cis-dichlorbis(triphenylphosphane)platinum(II) with the lithium compound obtained as the bromination product of 2-methylnaphthalene cis-bis(7-metyhylnaphth-1-yl)bis(triphenylphosphane)platinum(II) (6), has been isolated.The unexpected formation of 6 has been explained.